報價延遲最少15分鐘:2025/01/11 11:12 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.90/--
|
|
企業價值
2.59B
|
| 資產負債 |
|
每股賬面淨值
-1.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
622.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe. |